FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891729799> ?p ?o ?g. }

• W2891729799 endingPage "986" @default.
• W2891729799 startingPage "975" @default.
• W2891729799 abstract "Abstract Background A pharmacologic strategy for age‐related muscle weakness is desired to improve mortality and disability in the elderly. Angiotensin‐converting enzyme 2 (ACE2) cleaves angiotensin II into angiotensin 1‐7, a peptide known to protect against acute and chronic skeletal muscle injury in rodents. Since physiological aging induces muscle weakness via mechanisms distinct from other muscle disorders, the role of ACE2‐angiotensin 1‐7 in age‐related muscle weakness remains undetermined. Here, we investigated whether deletion of ACE2 alters the development of muscle weakness by aging and whether angiotensin 1‐7 reverses muscle weakness in older mice. Methods After periodic measurement of grip strength and running distance in male ACE2KO and wild‐type mice until 24 months of age, we infused angiotensin 1‐7 or vehicle for 4 weeks, and measured grip strength, and excised tissues. Tissues were also excised from younger (3‐month‐old) and middle‐aged (15‐month‐old) mice. Microarray analysis of RNA was performed using tibialis anterior (TA) muscles from middle‐aged mice, and some genes were further tested using RT‐PCR. Results Grip strength of ACE2KO mice was reduced at 6 months and was persistently lower than that of wild‐type mice ( p < 0.01 at 6, 12, 18, and 24‐month‐old). Running distance of ACE2KO mice was shorter than that of wild‐type mice only at 24 months of age [371 ± 26 vs. 479 ± 24 (m), p < 0.01]. Angiotensin 1‐7 improved grip strength in both types of older mice, with larger effects observed in ACE2KO mice (% increase, 3.8 ± 1.5 and 13.3 ± 3.1 in wild type and ACE2KO mice, respectively). Older, but not middle‐aged ACE2KO mice had higher oxygen consumption assessed by a metabolic cage than age‐matched wild‐type mice. Angiotensin 1‐7 infusion modestly increased oxygen consumption in older mice. There was no difference in a wheel‐running activity or glucose tolerance between ACE2KO and wild‐type mice and between mice with vehicle and angiotensin 1‐7 infusion. Analysis of TA muscles revealed that p16INK4a , a senescence‐associated gene, and central nuclei of myofibers increased in middle‐aged, but not younger ACE2KO mice. p16INK4a and central nuclei increased in TA muscles of older wild‐type mice, but the differences between ACE2KO and wild‐type mice remained significant ( p < 0.01). Angiotensin 1‐7 did not alter the expression of p16INK4a or central nuclei in TA muscles of both types of mice. Muscle ACE2 expression of wild‐type mice was the lowest at middle age (2.6 times lower than younger age, p < 0.05). Conclusions Deletion of ACE2 induced the early manifestation of muscle weakness with signatures of muscle senescence. Angiotensin 1‐7 improved muscle function in older mice, supporting future application of the peptide or its analogues in the treatment of muscle weakness in the elderly population." @default.
• W2891729799 created "2018-09-27" @default.
• W2891729799 creator A5000458736 @default.
• W2891729799 creator A5005476817 @default.
• W2891729799 creator A5007366188 @default.
• W2891729799 creator A5010101317 @default.
• W2891729799 creator A5013226731 @default.
• W2891729799 creator A5014575927 @default.
• W2891729799 creator A5021267745 @default.
• W2891729799 creator A5025308054 @default.
• W2891729799 creator A5032789085 @default.
• W2891729799 creator A5034910678 @default.
• W2891729799 creator A5040607451 @default.
• W2891729799 creator A5041559471 @default.
• W2891729799 creator A5042497531 @default.
• W2891729799 creator A5049596214 @default.
• W2891729799 creator A5049699552 @default.
• W2891729799 creator A5053448001 @default.
• W2891729799 creator A5054328043 @default.
• W2891729799 creator A5057901147 @default.
• W2891729799 creator A5059619179 @default.
• W2891729799 creator A5060960249 @default.
• W2891729799 creator A5064205368 @default.
• W2891729799 creator A5068972205 @default.
• W2891729799 creator A5073639538 @default.
• W2891729799 creator A5080124007 @default.
• W2891729799 creator A5082550661 @default.
• W2891729799 creator A5086099631 @default.
• W2891729799 date "2018-09-11" @default.
• W2891729799 modified "2023-10-16" @default.
• W2891729799 title "Angiotensin-converting enzyme 2 deficiency accelerates and angiotensin 1-7 restores age-related muscle weakness in mice" @default.
• W2891729799 cites W1898607618 @default.
• W2891729799 cites W1970453310 @default.
• W2891729799 cites W1974759520 @default.
• W2891729799 cites W1974985368 @default.
• W2891729799 cites W1976914294 @default.
• W2891729799 cites W1982481909 @default.
• W2891729799 cites W2004245295 @default.
• W2891729799 cites W2017614891 @default.
• W2891729799 cites W2025072503 @default.
• W2891729799 cites W2039177386 @default.
• W2891729799 cites W2054168325 @default.
• W2891729799 cites W2061075485 @default.
• W2891729799 cites W2069519394 @default.
• W2891729799 cites W2071843941 @default.
• W2891729799 cites W2072493014 @default.
• W2891729799 cites W2075340072 @default.
• W2891729799 cites W2081067390 @default.
• W2891729799 cites W2088074787 @default.
• W2891729799 cites W2094955667 @default.
• W2891729799 cites W2104822687 @default.
• W2891729799 cites W2113753544 @default.
• W2891729799 cites W2114360920 @default.
• W2891729799 cites W2121161073 @default.
• W2891729799 cites W2121616521 @default.
• W2891729799 cites W2123632642 @default.
• W2891729799 cites W2131604435 @default.
• W2891729799 cites W2150177691 @default.
• W2891729799 cites W2164350518 @default.
• W2891729799 cites W2312328558 @default.
• W2891729799 cites W244232182 @default.
• W2891729799 cites W2587681015 @default.
• W2891729799 cites W2593764183 @default.
• W2891729799 cites W2617764165 @default.
• W2891729799 cites W2765244546 @default.
• W2891729799 cites W326443903 @default.
• W2891729799 doi "https://doi.org/10.1002/jcsm.12334" @default.
• W2891729799 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6204583" @default.
• W2891729799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30207087" @default.
• W2891729799 hasPublicationYear "2018" @default.
• W2891729799 type Work @default.
• W2891729799 sameAs 2891729799 @default.
• W2891729799 citedByCount "34" @default.
• W2891729799 countsByYear W28917297992019 @default.
• W2891729799 countsByYear W28917297992020 @default.
• W2891729799 countsByYear W28917297992021 @default.
• W2891729799 countsByYear W28917297992022 @default.
• W2891729799 countsByYear W28917297992023 @default.
• W2891729799 crossrefType "journal-article" @default.
• W2891729799 hasAuthorship W2891729799A5000458736 @default.
• W2891729799 hasAuthorship W2891729799A5005476817 @default.
• W2891729799 hasAuthorship W2891729799A5007366188 @default.
• W2891729799 hasAuthorship W2891729799A5010101317 @default.
• W2891729799 hasAuthorship W2891729799A5013226731 @default.
• W2891729799 hasAuthorship W2891729799A5014575927 @default.
• W2891729799 hasAuthorship W2891729799A5021267745 @default.
• W2891729799 hasAuthorship W2891729799A5025308054 @default.
• W2891729799 hasAuthorship W2891729799A5032789085 @default.
• W2891729799 hasAuthorship W2891729799A5034910678 @default.
• W2891729799 hasAuthorship W2891729799A5040607451 @default.
• W2891729799 hasAuthorship W2891729799A5041559471 @default.
• W2891729799 hasAuthorship W2891729799A5042497531 @default.
• W2891729799 hasAuthorship W2891729799A5049596214 @default.
• W2891729799 hasAuthorship W2891729799A5049699552 @default.
• W2891729799 hasAuthorship W2891729799A5053448001 @default.
• W2891729799 hasAuthorship W2891729799A5054328043 @default.
• W2891729799 hasAuthorship W2891729799A5057901147 @default.
• W2891729799 hasAuthorship W2891729799A5059619179 @default.

• next